Pebblebrook Hotel Trust (NYSE:PEB) shares moved up 0.59% in last trading session and ended the day at $27.16. PEB Gross Margin is 39.30% and its has a return on assets of 2.30%. Pebblebrook Hotel Trust (NYSE:PEB) quarterly performance is -13.95%.
On 26 February, Pebblebrook Hotel Trust (NYSE:PEB) announced the winners of its fourth annual Pebby Awards. The Pebby Award winners were chosen for their outstanding accomplishments in 2015, as determined by the Company.
La Jolla Pharmaceutical Co. (NASDAQ:LJPC) caters to the Healthcare space. Its weekly performance is -9.52%. On the last day of trading company shares ended up at $15.39. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) distance from 50-day simple moving average (SMA50) is 2.90%.
On 25 February, La Jolla Pharmaceutical Co. (NASDAQ:LJPC) reported fourth quarter and full year 2015 financial results and highlighted 2015 corporate progress. La Jolla’s net cash used for operating activities for the three and twelve months ended December 31, 2015 was $8.5 million and $25.2 million, respectively, compared to net cash used for operating activities of $5.4 million and $12.9 million, respectively, for the same periods in 2014.
On 29 February, Third Point Reinsurance Ltd. (NYSE:TPRE) shares fell -1.60% and was closed at $11.05. Third Point Reinsurance Ltd. (NYSE:TPRE) year to date (YTD) performance is -17.60%.
On 26 February, Third Point Reinsurance Ltd. (NYSE:TPRE) reported Net income was $42.2 million, or 39 cents a share, compared with a loss of $14.7 million, or 14 cents, a year earlier, the Bermuda-based company said Thursday in a statement after the market closed.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell -2.48% in last trading session and ended the day at $7.87. OCUL Gross Margin is 83.30% and its has a return on assets of -37.20%. Ocular Therapeutix, Inc. (NASDAQ:OCUL) quarterly performance is -20.10%.
On 16 February, Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced the Phase 3 clinical development strategy for its OTX-TP (sustained release travoprost) drug product candidate for the treatment of glaucoma and ocular hypertension. Based on feedback from a recent meeting with the US Food and Drug Administration (FDA), Ocular Therapeutix intends to commence the first of two planned Phase 3 clinical trials in the third quarter of 2016.
ChemoCentryx, Inc. (NASDAQ:CCXI) caters to the Healthcare space. Its weekly performance is -7.84%. On the last day of trading company shares ended up at $3.29. ChemoCentryx, Inc. (NASDAQ:CCXI) distance from 50-day simple moving average (SMA50) is -6.16%.
ChemoCentryx, Inc. (NASDAQ:CCXI) announced that the Company’s fourth quarter 2015 financial results will be released after market close on Monday, March 14, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2016, to discuss these results and to answer questions.
Leave a Reply